
Equillium Inc (EQ) Stock Forecast & Price Target
Equillium Inc (EQ) Analyst Ratings
Bulls say
Equillium is a biotechnology company with a promising lead drug candidate, EQ504, for the treatment of severe autoimmune and inflammatory disorders such as UC and Celiac Disease. The company has a strong pipeline with potential catalysts in the near future, which could positively impact its value. The author maintains a positive outlook on Equillium, citing a differentiated safety profile and potential for widespread use of EQ504 in the treatment of UC.
Bears say
Equillium is a high-risk investment due to the uncertainties surrounding the effectiveness and safety of its lead drug, EQ504. While the drug has shown promise in early trials and has a buy rating, there are concerns about its potential in human subjects. With a projected peak sales of $3.15B, Equillium faces potential risks as a clinical-stage biotechnology company and further research is needed to validate the efficacy of its drug in treating severe autoimmune and inflammatory disorders.
This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.
Equillium Inc (EQ) Analyst Forecast & Price Prediction
Start investing in Equillium Inc (EQ)
Order type
Buy in
Order amount
Est. shares
0 shares